Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

산모의 HBsAg 보유 여부에 따른 만삭아의 B형간염 기본접종 및 무반응자에서 재접종 후 항체 양전율에 대한 연구

Comparison of the seroconversion rate after primary hepatitis B vaccination and after revaccination of non-responders in full-term infants according to mother's HBsAg seropositivity

  • 강장희 (좋은문화병원 소아청소년과) ;
  • 문재원 (왈레스기념 침례병원 소아청소년과) ;
  • 공승현 (좋은문화병원 소아청소년과) ;
  • 황광수 (좋은문화병원 소아청소년과) ;
  • 목지선 (좋은문화병원 소아청소년과) ;
  • 이현정 (좋은문화병원 소아청소년과)
  • 투고 : 2008.03.19
  • 심사 : 2008.09.02
  • 발행 : 2008.11.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목 적: 현재 우리나라에서는 B형 간염 백신접종 후 일률적으로 항체검사를 권장하지는 않으나, 아직도 우리나라의 성인 및 소아의 보유율이 외국에 비해 매우 높고, 영아기의 어린이집 등 단체생활 증가와 이로 인한 수평감염의 위험성이 높다고 생각되므로 영아기의 면역획득여부를 확인하는 것이 중요하다고 생각된다. 이에 본 연구에서는 출생 후 B형 간염 백신을 접종한 만삭아들을 대상으로 항체검사를 실시하여 산모가 보유자인 경우와 그렇지 않은 경우의 두 군으로 나누어 기본접종 후 항체 양전율을 평가하였고, 무반응자에서의 재접종 시 효과를 비교 분석하였다. 방 법: 2004년 10월부터 2007년 6월까지 문화병원에서 출생한 716명의 만삭아들을 대상으로 산모의 B형 간염 보유여부에 따라 두 군으로 나누어 현재 추천되고 있는 일정으로 기본접종 후 생후 7-12개월(산모가 보유자인 경우는 생후 9-15개월)에 항체가를 측정하여 기본접종의 효과를 비교하였다. 또한 각 군의 무반응자에게 3회 재접종을 실시하고 1-3개월 후 항체가를 측정하여 재접종의 효과를 비교하였다. 또한 보유자인 산모로부터 출생한 영아에서 산모의 HBeAg 양성 여부가 주산기 예방조치의 실패와 관련이 있는지 알아보았다. 결 과: HBsAg이 음성인 산모에서 태어난 총 662명의 건강한 만삭아에서 B형 간염 기본접종 후 623명(94.1%)에서 항체 양전되었고, HBsAg이 양성인 산모에서 태어난 만삭아중 감염된 4명의 영아를 제외한 50명에서는 39명(78%)이 기본접종 후 항체 양전되어 산모가 보유자가 아닌 경우가 더 높은 항체 양전율을 나타냈다(P<0.001). 또한 건강한 만삭아의 무반응자 39명중 32명에서 재접종 후 31명(96.9%)에서 항체가 양전되었고, 산모가 보유자인 무반응자 11명 중 8명에서 재접종 후 7명(87.5%)이 항체 양전되어 두 군의 무반응자에서의 재접종은 매우 효과적이었다. 또한 두 군에서 마지막 기본접종 후 항체검사시기에 따른 항체 양전율은 거의 차이가 없었다(P>0.05). HBeAg이 음성이고 HBsAg만 양성인 산모로부터 출생한 영아 40명 모두 예방이 되었고, HBeAg과 HBsAg 모두 양성인 산모로부터 출생한 14명중에서는 4명(28.6%)이 예방조치가 실패하였다. 이와 같이 산모의 HBeAg 양성여부는 주산기 예방조치의 실패와 밀접한 관련이 있었다(P<0.001). 결 론: 보유자가 아닌 산모로부터 출생한 건강한 만삭아에서 기본접종 후 무반응자의 재접종의 효과는 매우 좋았기 때문에, 가족 내에 보유자가 있거나 보유자가 없다 하더라도 확실한 효과를 위해서 기본접종 후 항체검사 및 재접종을 고려해야 할 것으로 생각되나, 이를 위해서는 현재 시행되지 않고 있는 일률적인 항체검사의 비용효과적인 측면에 대한 연구가 뒷받침되어야 할 것으로 사료되며, 산모가 보유자인 경우에는 항체 양전율이 감소하므로 수직감염이 되지 않았다 하더라도 산모로부터 수평감염의 위험이 높으므로 현재 추천되는 방법으로 반드시 항체검사를 실시하여 항체 양전여부를 확인해야 할 것이다.

Purpose : This study aimed to identify the true extent of non-responsiveness in full-term infants born from HBsAg-negative or HBsAg-positive mothers and vaccinated against hepatitis B virus (HBV) at 0, 1, and 6 months of age and to evaluate the effect of revaccination among non-responders. Methods : The study included 716 full-term infants born in 2004-2007. Of 716, 662 infants (A group) were born to HBsAg-negative mothers and 54 infants (B group: 50, except HBsAg-positive infants) were born to HBsAg-positive mothers. All infants were administered DNA recombinant vaccines at 0, 1, and 6 months of age. B group infants received hepatitis B immunoglobulin at birth. Anti-HBs titers were tested at 7-12 and 9-15 months in A and B groups, respectively. Three revaccination doses were administered to non-responders whose anti-HBs titers were under 10 mIU/ml; revaccinated infants were retested at 1-3 months after last vaccination. The association between HBeAg seropositivity of mother and the failure of HBV immunoprophylaxis was evaluated. Results : The seroconversion rates after primary hepatitis B vaccination were higher in A group (94.1%) than in B group (78%, P<0.001). The seroconversion rates were high in revaccinated infants (A group non-responders: 96.9%, B group non-responders: 87.5%). The failure of HBV immunoprophylaxis was significantly associated with maternal HBeAg seropositivity (P<0.001). Conclusion : The seroconversion rates after primary hepatitis B vaccination were low in B group infants. Revaccination of non-responders in B group was very effective. Therefore, anti-HBs testing and revaccination of B group is very important. Revaccination of non-responders in A group was also very effective. Thus, testing the immune status of infants born to HBsAg-negative mothers even after primary hepatitis B vaccination should be considered. However, to realize this, further studies on the cost-effectiveness of anti-HBs testing in healthy full-term infants are necessary.

키워드

참고문헌

  1. Kang HS, Song BC, Ji CX, Kim SY, Kim SK. Serologic markers of hepatitis B virus in pregnant women in Jeju Island. Korean J Hepatol 2004;10:191-6
  2. Choe BH. The management and treatment of chronic hepatitis B in Korean children. Korean J Pediatr 2007;50:823-34 https://doi.org/10.3345/kjp.2007.50.9.823
  3. Hepatitis B. In: LK Pickering, ed. Red Book: 2006 Report of the Committee on Infectious Diseases 27th ed. Elk Grove Village, IL: Committee on Infectious Diseases, American Academy of Pediatrics 2006;335-55
  4. Seo JH. Hepatitis B surface antigen and antibody positive rates of children and adolescents in Jeju. Korean J Hepatol 2003;9:304-14
  5. Park KS, Lee YS, Lee SG, Hwang JY, Chung WJ, Cho KB, et al. A study on markers of viral hepatitis in adults living in Daegu and Gyungbuk area. Korean J Gastroenterol 2003; 41:473-9
  6. Jang MK, Lee JY, Lee JH, Kim YB, Kim HY, Lee MS, et al. Seroepidemiology of HBV infection in South Korea, 1995 through 1999. Korean J Intern Med 2001;16:153-9 https://doi.org/10.3904/kjim.2001.16.3.153
  7. Shin BM, Yoo HM, Lee AS, Park SK. Seroprevalence of hepatitis B virus among health care workers in Korea. J Korean Med Sci 2006;21:58-62 https://doi.org/10.3346/jkms.2006.21.1.58
  8. Lee DH, Kim JH, Nam JJ, Kim HR, Shin HR. Epidemiological findings of hepatitis B infection based on 1998 national health and nutrition survey in Korea. J Korean Med Sci 2002;17:457-62 https://doi.org/10.3346/jkms.2002.17.4.457
  9. Seo K, Park SK, Kim YT, Park O. The prevalence of HBsAg positive parturients in Korea. Korean J Obstet Gynecol 2005;48:2119-24
  10. An YW, Chung EH, Rheem IS. A study of the current (2003-2005) prevalence of anti-HBs and immunologic memory of hepatitis B vaccine in children from the central area of Korea. Korean J Pediatr 2006;49:630-4 https://doi.org/10.3345/kjp.2006.49.6.630
  11. Zervou EK, Gatselis NK, Xanthi E, Ziciadis K, Georgiadou SP, Dalekos GN. Intrafamilial spread of hepatitis B virus infection in Greece. Eur J Gastroenterol Hepatol 2005;17:911-5 https://doi.org/10.1097/00042737-200509000-00005
  12. Ucmak H, Faruk Kokoglu O, Celik M, Ergun UG. Intrafamilial spread of hepatitis B virus infection in eastern Turkey. Epidemiol Infect 2007;135:1338-43
  13. Davis LG, Weber DJ, Lemon SM. Horizontal transmission of hepatitis B virus. Lancet 1989;1:889-93
  14. Deertekin H, Tuzcu A, Yalin K. Horizontal transmission of HBV infection among students in Turkey. Public Health 2000;114:411-2 https://doi.org/10.1038/sj.ph.1900684
  15. Kim YS, Ahn YO. Factors associated with intrafamilial transmission of hepatitis B virus infection in Korea. J Korean Med Sci 1993;8:395-404 https://doi.org/10.3346/jkms.1993.8.6.395
  16. Belloni C, Tinelli C, Orsolini P, Pistorio A, Avanzini A, Moretta A, et al. Revaccination against hepatitis B virus of non-responding and low-responding infants immunised at birth. A parallel evaluation of rubella and tetanus vaccine. Vaccine 1998;16:399-402 https://doi.org/10.1016/S0264-410X(97)80917-6
  17. Shivananda, Somani V, Srikanth BS, Mohan M, Kulkarni PS. Comparison of two hepatitis B vaccines (GeneVac-B and Engerix-B) in healthy infants in India. Clin Vaccine Immunol 2006;13:661-4 https://doi.org/10.1128/CVI.00087-06
  18. Committee on Infectious Disease, Korean Pediatric Society. Vaccine Q & A. 2nd ed 2006:19-26
  19. Kim YD, Han MK, Kim AE, Kim KS, Pi SY. Immune responses of hepatitis B vaccination among very low birth weight infant. Korean J Pediatr 2006;49:857-63 https://doi.org/10.3345/kjp.2006.49.8.857
  20. Hasanjani Roushan MR, Pasha YZ, Saghebi R, Kohi F. Revaccination of non-responding infants delivered by HBsAg-positive mothers. Eur J Clin Microbiol Infect Dis 2005;24:434-5 https://doi.org/10.1007/s10096-005-1340-8
  21. Prakash C, Bhatia R, Kumari S, Verghese T, Datta KK. Response to hepatitis B vaccination in high risk population. J Commun Dis 2000;32:17-21
  22. Lazizi Y, Badur S, Perk Y, Ilter O, Pillot J. Selective unresponsiveness to HBsAg vaccine in newborns related with an in utero passage of hepatitis B virus DNA. Vaccine 1997; 15:1095-100 https://doi.org/10.1016/S0264-410X(97)00005-4
  23. Hieu NT, Kim KH, Janowicz Z, Timmermans I. Comparative efficacy, safety and immunogenicity of Hepavax-Gene and Engerix-B, recombinant hepatitis B vaccines, in infants born to HBsAg and HBeAg positive mothers in Vietnam: an assessment at 2 years. Vaccine 2002;20:1803-8 https://doi.org/10.1016/S0264-410X(01)00518-7
  24. Yen YH, Chen CH, Wang JH, Lee CM, Changchien CS, Lu SN. Study of hepatitis B (HB) vaccine non-responsiveness among health care workers from an endemic area (Taiwan). Liver Int 2005;25:1162-8 https://doi.org/10.1111/j.1478-3231.2005.01157.x
  25. Ukena T, Esber H, Bessett R, Parks T, Crocker B, Shaw F. Site of injection and response to hepatitis B vaccine. N Engl J Med 1985;313:579-80
  26. Fisman DN, Agrawal D, Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin Infect Dis 2002;35:1368-75 https://doi.org/10.1086/344271
  27. Lau YL, Tam A, Ng KW, Tsoi NS, Lam B, Lam P, et al. Response of preterm infants to hepatitis B vaccine. J Pediatr 1992;121:962-6 https://doi.org/10.1016/S0022-3476(05)80352-X
  28. Bock HL, Kruppenbacher J, Snger R, Hbel W, Clemens R, Jilg W. Immunogenicity of a recombinant hepatitis B vaccine in adults. Arch Intern Med 1996;156:2226-31 https://doi.org/10.1001/archinte.156.19.2226
  29. Chan W, Petric M, Wang E, Koren G, Read S, Blanchette V. Response to hepatitis B immunization in children with hemophilia: relationship to infection with human immunodeficiency virus type 1. J Pediatr 1990;117:427-30 https://doi.org/10.1016/S0022-3476(05)81086-8
  30. Kruskall MS, Alper CA, Awdeh Z, Yunis EJ, Marcus-Bagley D. The immune response to hepatitis B vaccine in humans: inheritance patterns in families. J Exp Med 1992;175:495-502 https://doi.org/10.1084/jem.175.2.495
  31. Jafarzadeh A, Shokri F. The antibody response to HBs antigen is regulated by coordinated Th1 and Th2 cytokine production in healthy neonates. Clin Exp Immunol 2003;131: 451-6 https://doi.org/10.1046/j.1365-2249.2003.02093.x
  32. Jafarzadeh A, Zarei S, Shokri F. Low dose revaccination induces robust protective anti-HBs antibody response in the majority of healthy non-responder neonates. Vaccine 2008; 26:269-76 https://doi.org/10.1016/j.vaccine.2007.10.044
  33. Zhuang GH, Yan H, Wang XL, Hwang LY, Wu Q, Wang LR, et al. Hepatitis B revaccination in healthy non-responder Chinese children: five-year follow-up of immune response and immunologic memory. Vaccine 2006;24:2186-92 https://doi.org/10.1016/j.vaccine.2005.11.004
  34. Kim MJ, Nafziger AN, Harro CD, Keyserling HL, Ramsey KM, Drusano GL, et al. Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response. Vaccine 2003;21:1174-9 https://doi.org/10.1016/S0264-410X(02)00626-6
  35. Song YM, Sung J, Yang S, Choe YH, Chang YS, Park WS. Factors associated with immunoprophylaxis failure against vertical transmission of hepatitis B virus. Eur J Pediatr 2007;166:813-8 https://doi.org/10.1007/s00431-006-0327-5
  36. Jeong O, Kim JH. The outcome of perinatal prophylaxis for HBeAg positive mothers according to the maternal HBVDNA levels at the delivery time. Korean J Pediatr 2007;50: 348-54 https://doi.org/10.3345/kjp.2007.50.4.348
  37. Hammitt LL, Hennessy TW, Fiore AE, Zanis C, Hummel KB, Dunaway E, et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine 2007;25: 6958-64 https://doi.org/10.1016/j.vaccine.2007.06.059
  38. Williams IT, Goldstein ST, Tufa J, Tauillii S, Margolis HS, Mahoney FJ. Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Pediatr Infect Dis J 2003;22:157-63
  39. Zanetti AR, Mariano A, Romano L, D'Amelio R, Chironna M, Coppola RC, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005;366:1379-84 https://doi.org/10.1016/S0140-6736(05)67568-X
  40. Samandari T, Fiore AE, Negus S, Williams JL, Kuhnert W, McMahon BJ, et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 2007;120:e373-81 https://doi.org/10.1542/peds.2007-0131